ConductScience.org, home

Paper71868

Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months.

Gordon BL and 1 other. Ann Allergy, 1977. Cited by 31 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months. Papers, record 71868. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/71868

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months.
PubMed
Journal
Ann Allergy
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
1.34
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gordon BL 2ndB L
2Yanagihara RR

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LevamisoleMajor topic
Lupus Erythematosus, SystemicMajor topic
T-LymphocytesMajor topic
Antibodies, Antinuclear
B-Lymphocytes
Follow-Up Studies
Humans
Morbidity
Neutrophils
Prednisone
Rosette Formation

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
7873092Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.Drug Saf1994https://conductscience.org/library/papers/7873092PubMed
7009134Antirheumatic drugs: clinical pharmacology and therapeutic use.Drugs1980https://conductscience.org/library/papers/7009134PubMed
6295108Lysosomal enzymes and metabolic activity of polymorphonuclear leukocytes from patients with systemic lupus erythematosus and from experimental animals after levamisole treatment.Agents Actions1982https://conductscience.org/library/papers/6295108PubMed
6232853Thiabendazole-induced suppression of renal damage in a murine model of autoimmune disease.Am J Pathol1984https://conductscience.org/library/papers/6232853PubMed
2702118The treatment of lupus nephritis.Pediatr Nephrol1989https://conductscience.org/library/papers/2702118PubMed
742911In vitro thymosin- and levamisole-induced increase of lymphocyte transformation in psoriatic patients.Arch Dermatol Res1978https://conductscience.org/library/papers/742911PubMed
119598In vivo effect of levamisole on cellular and humoral immunity in normal chickens.Clin Exp Immunol1979https://conductscience.org/library/papers/119598PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/71868

GET https://conductscience.org/api/papers/v1/71868/authors